Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors

Area of Science:

• Oncology
• Immunotherapy
• Thoracic Surgery

Background:

• T-cell checkpoint inhibitors, including programmed death receptor-1 (PD-1) and programmed death-ligand 1 (PD-L1) therapies, are approved for metastatic non-small cell lung cancer (NSCLC).
• The use of these immunotherapies as neoadjuvant treatment prior to surgery remains under investigation.
• Autoimmune toxicities, particularly pneumonitis, pose a significant concern in the perioperative period.

Observation:

• This case series presents the initial evaluation of 5 patients who underwent pulmonary resection after receiving PD-1/PD-L1 inhibitor therapy.
• The study focuses on identifying potential safety concerns and technical challenges associated with surgical intervention in this patient cohort.

Findings:

• The study details the safety profile and technical aspects of performing pulmonary resections in patients treated with PD-1/PD-L1 inhibitors.
• Specific adverse events and surgical considerations are described, providing novel insights into perioperative management.

Implications:

• This research provides the first evidence regarding the safety and technical feasibility of pulmonary resection following PD-1/PD-L1 inhibitor therapy.
• Findings may inform clinical decision-making for neoadjuvant immunotherapy in non-small cell lung cancer patients undergoing surgical resection.
• Further investigation is warranted to optimize perioperative strategies and manage potential immune-related adverse events.